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Abstract: Glucocorticoids are widely used anti-inflammatory medication in diseases like asthma and chronic obstructive pulmonary 
disease. Glucocorticoids can either activate (transactivation) or inhibit (transrepression) transcription. RU24858 was introduced as a 
“dissociated” glucocorticoid and it has been reported to transrepress but not to transactivate. The aim of this study was to compare the 
effects of RU24858 and dexamethasone in human neutrophils. RU24858 delayed spontaneous neutrophil apoptosis and further enhanced 
GM-CSF- induced neutrophil survival to a similar extent as dexamethasone. Like dexamethasone RU24858 also reduced CXCL8 
and MIP-1α. Unexpectedly however, RU24858 increased the expression of the glucocorticoid-inducible genes BLT-1,  Annexin-1 and 
Grb-2 in neutrophils to a similar level as seen with dexamethasone. We have shown here that dexamethasone and RU24858 both 
increase Grb-2, BLT1 and Annexin-1 expression and inhibit CXCL8 and MIP-1α production. This suggests that RU24858 was not able 
to dissociate between transactivation and transrepression in human neutrophils but enhanced neutrophil survival.
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Introduction
Neutrophils have an important role in the  pathogenesis of 
chronic obstructive pulmonary disease (COPD), severe 
asthma, rheumatoid arthritis and many other inflam-
matory diseases.1–3 Glucocorticoids are widely used 
to treat many inflammatory conditions such as COPD, 
asthma and rheumatoid arthritis.4  Glucocorticoids act 
by entering the cell and binding to the glucocorticoid 
receptor (GR) in the cytoplasm leading to GR activa-
tion and nuclear import.4 Inside the nucleus the glu-
cocorticoid-GR complex can induce gene transcription 
(transactivation) by binding to specific DNA sequences 
called glucocorticoid response elements (GREs) in the 
promoter region of steroid responsive genes. The glu-
cocorticoid-GR complex can also inhibit pro-inflam-
matory transcription factors such as nuclear factor-κB 
(NF-κB) and activator protein (AP)-1. This interaction 
results in down-regulation of proinflammatory gene 
transcription (transrepression).4,5
Glucocorticoids which only have the ability to tran-
srepress but not transactivate, known as dissociated 
steroids, have been developed based on the hypoth-
esis that the metabolic side-effects of glucocorticoids 
such as regulation of calcium and glucose metabolism 
are due to transactivation but the anti- inflammatory 
effects derive from transrepression.6,7 RU24858 is 
one such compound and in human and murine cell 
lines the transrepression capability of RU24858 was 
shown to be almost comparable to dexamethasone. In 
contrast to dexamethasone, RU24858 showed almost 
nonexistent transactivation potency.67,8 Surprisingly 
when studying in vivo a rat model of lung inflam-
mation, Belvisi et al9 could not see any dissociation 
between the anti-inflammatory activity and metabolic 
side effects of RU24858. Furthermore, RU24858 did 
not dissociate between transactivation and transre-
pression in primary human eosinophils.10
Glucocorticoids can suppress inflammation in part 
via modulation of inflammatory cell apoptosis.11 Apop-
tosis is a form of programmed cell death and it has been 
shown to be important in the resolution of pulmonary 
inflammation.2,12 Dibbert et al13 reported that neutro-
phil apoptosis is delayed in inflammatory lung dis-
eases such as cystic fibrosis, pneumonia and idiopathic 
fibrosis. Apoptosis is characterized by shrinkage of the 
cells, nuclear condensation and  formation of apoptotic 
bodies. These apoptotic cells are then phagocytosed 
intact by macrophages. This allows the cell death to 
occur with no leakage of intracellular contents and 
no accompanying inflammation.12,14 In contrast to the 
induction of eosinophil15 and lymphocyte16 apopto-
sis, glucocorticoids decrease neutrophil apoptosis.17–19 
This may account for the increased neutrophilia 
seen in severe asthmatics treated with high doses of 
glucocorticoids.20,21 If neutrophilia in severe asthma is 
an iatrogenic phenomenon due to inhibition of neu-
trophil apoptosis by glucocorticoids, a glucocorticoid 
able to suppress inflammation, but devoid of ability 
to suppress neutrophil apoptosis could potentially be 
beneficial in the treatment of these patients. However, 
there are no published data as to whether transactiva-
tion and/or transrepression events play a role in the 
regulation of apoptosis in human neutrophils. A gluco-
corticoid differentiating between transactivation and 
transrepression in neutrophils would be an excellent 
tool to address this question.
The aim of this study was to assess the functional 
consequences of dexamethasone and RU24858 on 
protein expression in neutrophil as well as in neu-
trophil apoptosis. We have shown here that dexam-
ethasone and RU24858 both induce BLT1, Annexin 1 
and Grb-2 expression as well as inhibit CXCL8 and 
MIP-1α production. Both steroids also inhibit spon-
taneous neutrophil apoptosis.
Methods
neutrophil isolation
Neutrophils were isolated under sterile conditions as 
previously reported.18,19 After obtaining an informed 
consent to a study protocol accepted by the ethical 
committee of Tampere University Hospital, venous 
blood (50 mL) was collected from normal individuals 
into 10–20 mL of acid citrate dextrose anticoagulant 
and hydroxyethyl starch solution. White blood cells 
were obtained from the upper layer and were over-
laid onto Ficoll and centrifuged at 700 g for 30 min 
at 20°C. The mononuclear cell layer was removed 
and the remaining pellet containing granulocytes and 
red blood cells was washed in HBSS (Hank’s Bal-
anced Salt Solution without Phenol Red). Red blood 
cells were lysed by hypotonic lysis. Neutrophils were 
washed with RPMI 1640 (2% fetal calf serum and 
5 mM EDTA), stained with Kimura and counted 
using microscopy. Only neutrophil populations with 
purity of .99% were used accepted for experiments. 
Cells were incubated in the presence and absence of 
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RU24858 or dexamethasone. Both steroids were dis-
solved in DMSO. The final concentration of DMSO 
in the cells was 0.1% and the same concentration of 
DMSO was used in control experiments.
Flow cytometry
Unless otherwise stated the percentage of apoptotic 
cells was measured using a relative DNA fragmenta-
tion assay in propidium iodide stained cells by flow 
cytometry as previously described18,19 after culture for 
16 h. The cells showing decreased relative DNA con-
tent were considered as apoptotic.
To determine BLT1 and Annexin-1 expression, 
neutrophils were cultured for 20 h in the presence 
or absence of RU24858 or dexamethasone. BLT1 
and Annexin-1 expression was determined by using 
anti-BLT1-PE or anti-Annexin-1 antibodies with the 
corresponding PE labelled anti-mouse secondary 
antibody. For comparison an isotype control antibody 
was used. Briefly, after culture cells were washed and 
incubated for 30 min with primary antibody on ice. 
After incubation cells were washed 3 times. Anti-
Annexin-1 labelled cells were further labelled with 
1:100 secondary antibody for 30 min on ice. After 
incubation cells were washed once more with PBS 
containing 1% BSA and analysed by flow cytometry.
For determination of Grb-2 expression, neutrophils 
were cultured for 6 h in the presence or absence of 
RU24858 or dexamethasone. Grb-2 expression was 
determined by using anti-Grb-2 antibody. A PE-con-
jugated anti-mouse IgG secondary antibody was used 
for detection and an isotype-control antibody used to 
confirm specificity. Briefly, after culture cells were 
centrifuged and incubated in PBS containing 0.25% 
formaldehyde for 30 min at room temperature. After 
incubation 1 mL PBS with 10% fetal calf serum was 
added and cells were centrifuged. Cells were then 
incubated for 10 min at 4°C in 200 µL PBS with 10% 
fetal calf serum and 0.025% saponin.  Thereafter the 
cells were centrifuged (400 g for 5 min) and suspended 
in PBS solution containing 10% fetal calf serum and 
0.025% saponin and the antibody (1:100). After 1 h 
incubation samples were washed twice with PBS con-
taining 10% fetal calf serum and 0.025% saponin and 
finally the secondary antibody was added and cells 
were incubated for 1 h. After incubation cells were 
once more washed with PBS containing 10% fetal 
calf serum and analysed with flow cytometry.
Cytokine measurement
Neutrophils were cultured in the presence or absence 
of a range of concentrations of RU24858 or dex-
amethasone (both 0.01–1 µM) and the appropriate 
 stimulus. After culture for 18 h supernatants were 
collected and stored at −20°C. Cytokines were mea-
sured by ELISA-based assays.
Morphological analysis
Cells were centrifuged onto cytospin slides. After fixation 
in methanol slides were stained with May-Grünwald-
 Giemsa. Cells showing typical features of apoptosis such 
as condensation of chromatin, nuclear coalescence and 
shrinkage of the cell were considered as apoptotic.
Materials
RU24858 was obtained from Aventis Pharma, 
Romainville Cedex, France. Dexamethasone and 
propidium iodide and anti-Grb-2 antibody and PE-
conjugated secondary antibody were purchased from 
Sigma Chemical Co. (St. Louis, MO). Anti-BLT1-PE, 
anti-Annexin-1 and PE-conjugated Rat anti-mouse 
secondary were purchased from BD Biosciences 
(Franklin Lakes, NJ). Other reagents were obtained 
as follows: antibiotics, fetal calf serum, RPMI 1640 
(Gibco BRL, Paisley, Scotland, UK), GM-CSF and 
DuoSet ELISA Development System for IL-8/CXCL8 
and MIP-1α (R&D system Europe, Abingdon, UK), 
May-Grünwald (Merck, Darmstadt, Germany), and 
Giemsa (J.T. Baker, Deventer, Holland).
Statistics
Data is expressed as mean ± SEM. Differences 
were analyzed by analysis of variance supported by 
 Student-Newman-Keuls test and they were consid-
ered significant when P , 0.05.
Results
effects of dexamethasone and rU24858 
on spontaneous neutrophil survival
Glucocorticoids such as dexamethasone are known 
to enhance neutrophil survival by inhibiting 
apoptosis.18,22,23 As expected dexamethasone inhibited 
constitutive neutrophil apoptosis (Fig. 1; Table 1). 
RU24858 (0.1–1 µM) also enhanced spontaneous 
neutrophil survival in a concentration-dependent 
manner by inhibiting apoptosis (Fig. 1). Analysis of 
morphological features of apoptosis also confirmed 
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that dexamethasone and RU24858 (both at 1 µM) 
inhibit spontaneous neutrophil apoptosis to a simi-
lar extent (Table 2). No statistically significant dif-
ferences between corresponding concentrations of 
RU24858 and Dexamethasone could be seen.
effects of dexamethasone  
and rU24858 on gM-CSF-afforded 
neutrophil survival
As expected, dexamethasone further enhanced the 
survival of GM-CSF treated human neutrophils as 
evidenced by reduced number of cells showing hypo-
diploid DNA content (Table 1) or morphological 
features of apoptosis (Table 2). RU24858 had a simi-
lar effect on neutrophil apoptosis as dexamethasone 
(Tables 1 and 2). RU24858 further enhanced GM-
CSF-induced neutrophil survival independently of 
the concentration of GM-CSF (7–700 pM) (Table 1). 
Similar results were obtained using morphological 
signs of apoptosis as a readout (Table 2). No statis-
tically significant differences between correspond-
ing concentrations of RU24858 and Dexamethasone 
were observed. Taken together, the effect of RU24858 
on spontaneous human neutrophil apoptosis and GM-
CSF-induced neutrophil survival is similar to that of 
the classical glucocorticoid dexamethasone.
effects of dexamethasone  
and rU24858 on cytokine production
Glucocorticoids have previously been reported to inhibit 
the NF-κB regulated CXCL8 and MIP-1α expres-
sion in neutrophils24,25 and therefore we compared the 
effects of dexamethasone and RU24858 on the pro-
duction of those inflammatory factors.  Spontaneous 
CXCL8 and MIP-1α production was low and LPS 
(100 ng/mL) and TNF-α (1 ng/mL) increased CXCL8 
(Fig. 2A and B) and MIP-1α (Fig. 3A and B) produc-
tion 6–20-fold. Both dexamethasone (0.1–1 µM) and 
RU24858 (0.1–1 µM) inhibited CXCL8 (Fig. 2A and B) 
and MIP-1α (Fig. 3A and B) generation in a concentra-
tion-dependent manner and there were no statistically 
significant differences between corresponding concen-
trations of RU24858 and Dexamethasone.
effects of dexamethasone and rU24858 
on Leukotriene B4 receptor 1 (BLT-1), 
Annexin-1 and growth Factor receptor 
bound protein 2 expression
BLT-1 and Annexin-1 expression is upregulated 
by GR via a GRE-mediated mechanism in human 
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Figure 1. The effects of rU24858 and dexamethasone on spontane-
ous neutrophil apoptosis. Apoptosis was determined by the relative DnA 
fragmentation assay and flow cytometry in propidium iodide-stainded 
neutrophils.
notes: Values are the mean ± S.e.M., n = 7. results are expressed 
as percentage of apoptotic cells. *indicates P , 0.05, **P , 0.01, 
***P , 0.001 as compared with the respective control in the absence of 
glucocorticoids.
Table 1. The effects of dexamethasone and rU24858 on apoptosis of human neutrophils in the presence and absence of 
gM-CSF as analyzed by the relative DnA fragmentation assay.
Apoptotic neutrophils %
control GM-csF (7 pM) GM-csF (70 pM) GM-csF (700 pM)
Control 58.9 ± 2.3 38.1 ± 4.1 35.8 ± 4.1 33.0 ± 3.3
rU24858 (1 µM) 43.8 ± 5.4** 24.5 ± 2.8* 24.0 ±1.8** 26.3 ± 2.3**
Dexamethasone (1 µM) 41.2 ± 7.3*** 29.5 ± 5.8 26.8 ± 3.4* 27.1 ± 4.9*
notes: Apoptosis was analyzed by the relative DnA fragmentation assay. results are expressed as percentage of apoptotic neutrophils. Values are the 
mean ± S.e.M., n = 7. *indicates P , 0.05, **P , 0.01, ***P , 0.001 as compared with the respective control in the absence of glucocorticoids.
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Table 2. The effects of dexamethasone and rU24858 on apoptosis of human neutrophils in the presence and absence of 
gM-CSF as analyzed by morphological criteria.
Apoptotic neutrophils %
control GM-csF (70 pM) GM-csF (700 pM)
Control 50.5 ± 6.2 30.4 ± 3.7 26.5 ± 2.8
rU24858 (1 µM) 28.8 ± 4.6*** 17.2 ± 3.0** 16.5 ± 2.3**
Dexamethasone (1 µM) 25.4 ± 3.3*** 13.8 ± 1.8** 14.5 ± 2.2**
notes: Apoptosis was analyzed by morphological criteria. All results are expressed as percentage of apoptotic neutrophils. Values are the mean ± S.e.M., 
n = 6 *indicates P , 0.05, **P , 0.01, ***P , 0.001 as compared with the respective control in the absence of glucocorticoids.
neutrophils.26,27 Both dexamethasone (1 µM) and 
RU24858 (1 µM) both enhanced both BLT-1 and 
Annexin-1 expression (Fig. 4A and B). We also mea-
sured Grb-2 expression. Grb-2 is an adaptor protein 
involved in signal transduction and glucocorticoids 
have been shown to reduce its recruitment to recep-
tor complexes by an indirect mechanism.28 Again 
both dexamethasone (1 µM) and RU24858 (1 µM) 
enhanced Grb-2 expression (Fig. 4C). Differences 
between corresponding concentrations of RU24858 
and Dexamethasone were not statistically significant. 
To exclude the possibility that RU24858 affects the 
fluorescence properties of the FITC-conjugated sec-
ondary antibody, its effects were studied on cells 
labelled with a FITC-conjugated isotype control anti-
body only. RU24858 (0.01 µM–1 µM) and dexam-
ethasone (1 µM) had no effect on the fluorescence of 
isotype control (n = 6, data not shown).
Discussion
We report here the effects of the putative “dissociated 
steroid” RU24858 in primary human neutrophils. 
Our results show that the dissociated glucocorticoid 
RU24858 induces constitutive neutrophil survival 
as well as GM-CSF-induced neutrophil survival. 
RU24858 acts as a transrepressor in human neutro-
phils but in contrast to our expectations, RU24858 
had a similar ability as dexamethasone to induced 
transactivation in human neutrophils as evidenced by 
increased BLT-1, Annexin-1 and Grb-2  expression. 
Thus, the present results suggest that RU24858 does 
not act as a dissociated steroid in primary human 
neutrophils.
Many of the anti-inflammatory effects of glu-
cocorticoids are believed to be due to inhibition of 
activated pro-inflammatory transcription factors, 
whereas the metabolic and other adverse effects 
may derive from transactivation via GREs. It was 
hypothesised, therefore, that it would be possible 
to separate positive anti-inflammatory effects from 
the side effects of glucocorticoids, by developing 
novel compounds which could transrepress but not 
 transactivate. RU24858 is such a dissociated gluco-
corticoid. In human and murine cells, RU24858 is 
almost as effective as dexamethasone in inducing tran-
srepression but showed little or no transactivation.6,7 
In this study, as expected, we demonstrated that both 
dexamethasone and RU24858 repressed CXCL8 and 
MIP-1α production to a similar extent indicating that 
RU24858 possess a transrepression capacity.
The transactivation profile of RU24858 in rat 
HTC cells, murine L929 fibroblast, human THP 1, 
Hela and A549 cells has been reported to be almost 
negligible.6,7,29 However, an equivalent transactiva-
tion activity as compared with prednisolone was 
reported in the African green monkey kidney fibro-
blast cell line, CV-1.8 Furthermore, no dissociation 
between anti-inflammatory activity and side effects 
was reported in in vivo animal models.9 Therefore, the 
activity profile of RU24858 has been proposed to be 
divergent and with some species and cell  selectivity. 
Only one study to date has reported the activity pro-
file of RU24858 in primary human cells and this 
reports that RU24858 is not dissociated in primary 
human eosinophils.10 In the present study we demon-
strate that RU24858 also does not dissociate between 
transrepression and transactivation in human neutro-
phils supporting the evidence in in vivo animal mod-
els and primary human eosinophils. Taken together, 
these results suggest that studies in transfected cell 
lines can lead to anomalous conclusions. This may 
be due to abnormal expression and or integration of 
key receptors and GR- and inflammation-associated 
signalling pathways.30
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In human eosinophils RU24858 was less potent 
than dexamethasone and mometasone in suppress-
ing cytokine production and inducing apoptosis.10 
In contrast, RU24848 had a similar efficacy to dex-
amethasone in repressing transcription in mouse 
macrophages.31 Furthermore, RU24858 inhibited the 
expression of tristetraprolin at the level of mRNA 
and protein expression in J774 mouse macrophages 
at concentrations used in the present study.32 In the 
present study dexamethasone and RU2485 sup-
pressed cytokine production in human neutrophils to 
a similar extent. A possible explanation for the dif-
ferences in potency and the divergent dissociation 
abilities of this compound is that RU24858 works as 
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Figure 2. The effects of rU24858 and dexamethasone on CXCL8 
production in human neutrophils. LPS (100 ng/mL; A) and TnF-α (1 ng/mL; 
B) were used to stimulate CXCL8 production. CXCL8 production was 
analyzed by eLiSA.
notes: Values are the mean ± S.e.M., n = 6. results: *indicates P , 0.05, 
**P , 0.01 and ***P , 0.001 as compared with the respective control in 
the presence of LPS or TnF-α but in the absence of glucocorticoids.
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Figure 3. The effects of rU24858 and dexamethasone on MiP-1α pro-
duction in human neutrophils. LPS (100 ng/mL; A) and TnF-α (1 ng/mL; 
B) were used to stimulate MiP-1α production in cells. MiP-1α production 
was analyzed by eLiSA.
notes: Values are the mean ± S.e.M., n = 6. results; *indicates P , 0.05, 
**P , 0.01 and ***P , 0.001 as compared with the respective control in 
the presence of LPS or TnF-α but in the absence of glucocorticoids.
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a  partial agonist at GR. In cells where the numbers 
of receptors or signal transduction efficiency is high 
it works as a full agonist. In contrast, in cells where 
the number of receptors is low or the efficiency of 
signal transduction is poor it may produce a maximal 
response that is less than that of the full agonist or it 
may even be an antagonist. Use of cells from differ-
ent species may also lead to variability in results, as 
different species demonstrate divergent sensitivities 
to glucocorticoids.
Post-transcriptional mechanisms as well as inter-
actions and synergy with other transcription factors 
can affect the transactivation and transrepression pro-
file of glucocorticoids, giving a possible reason for 
noncanonical effects.33 Indeed Chivers et al29 showed 
a RU24858 unable to induce classical GRE medi-
ated transactivation while being able to activate non-
 traditional GC mediated gene expression. To be able 
to asses GRE- mediated traditional activation of tran-
scription we studied Annexin-1 and BLT-1 expression. 
They both have GREs in their promoters and have 
been shown to be induced in GRE-mediated man-
ner in human neutrophils.26,27 Additionally, we also 
studied Grb2 expression, which was also increased 
by glucocorticoid treatment. Grb2 is not known to 
have GRE in its promoter region and as such is a non-
 traditional glucocorticoid dependent protein. Unlike 
previously reported in adenocarcinomic human alveo-
lar basal epithelial cells A549,29 in human neutrophils 
RU24858 was able to activate both traditional GRE-
dependent as well as nontraditional gene transcription 
further supporting that the transactivation effects of 
“dissociated glucocorticoids” are cell type dependent. 
GR exists as at least 8 functional isoforms.34 These 
GR isoforms display diverse transcriptional activities 
and the levels of these isoforms vary among differ-
ent cell types. Whether this cell type-specific isoform 
profile of GR activation can explain why RU24858 
has divergent transcription profile depending on cell 
type remains to be investigated.
Glucocorticoids are widely used to treat inflamma-
tory diseases such as rheumatoid arthritis, COPD and 
severe asthma that are characterised with a marked 
neutrophilic inflammatory component. Apoptosis of 
neutrophils and its regulation by cytokines such as 
GM-CSF and by glucocorticoids is considered to be an 
important pathogenic event in several diseases.13,15,35 
Glucocorticoids can either up- or down-regulate the 
expression of a large number of genes. In peripheral 
blood monocytes, Galon et al36 found that 12% of 
the 9182 genes examined were up-regulated and 9% 
were down-regulated by glucocorticoids. However, 
the role of glucocorticoid-mediated transactivation or 
transrepression events in the regulation of neutrophil 
apoptosis is unclear.
Neutrophils are terminally differentiated, very short-
lived non-dividing cells. Thus, molecular techniques 
are difficult to perform in these cells. For this reason, 
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Figure 4. The effects of rU24858 and dexamethasone on BLT-1 (A) and Annexin-1 (B) and grb-2 (c) expression in human neutrophils. Cells were stained 
and analyzed by using flow cytometry.
notes: Results are shown as mean fluorescence intensity following treatment of cells with dexamethasone (0.01–1 µM) and rU24858 (0.01–1 µM). 
 Values are the mean ± S.e.M., n = 4 (A and B) or n = 6 (c). *indicates P , 0.05, **indicates P , 0.01 as compared with the respective control in the 
absence of glucocorticoids.
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a pharmacological approach to dissecting out GR 
mechanisms is the only viable approach. The main aim 
of our study was to determine whether the “dissociated 
steroid” RU24858 could be a useful pharmacological 
tool to further enable elucidation of the GR mecha-
nisms involved in neutrophil survival. Unfortunately, 
RU24858 does not dissociate between transactivation 
and transrepression in human neutrophils and thus is 
not suitable to evaluating GR mechanisms in primary 
human neutrophils. Functionally, RU24858 has similar 
effects to dexamethasone and inhibits spontaneous neu-
trophil apoptosis and  further enhances cytokine-induced 
survival of human  neutrophils. Clinically, RU24858 
would be expected to have a similar profile as inhaled 
corticosteroids which in human may result in the tissue 
neutrophilia seen in severe asthma and may balance sen-
sitivity to infection during glucocorticoid treatment.20,21
conclusions
In conclusion, we report here that RU24858 and dex-
amethasone both induce Grb-2, BLT1 and Annexin-1 
expression and inhibit CXCL8 and MIP1α  production. 
RU24858 does not dissociate between transactivation 
and transrepression in non-malignant primary human 
neutrophils but enhances neutrophil survival similarly 
to dexamethasone.
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